Paclitaxel and cisplatin combined with anlotinib as first line regimen for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, multicentre open-label phase II clinical trial

被引：0
|
作者：
Wang, J-S. [1 ]
Wu, T. [1 ]
Hong, Y-G. [1 ]
Guo, Y-Z. [2 ]
Luo, S-X. [3 ]
Li, N. [3 ]
Cheng, Y-F. [4 ]
Li, B-S. [5 ]
机构：
[1] Anyang Tumour Hosp, Dept Med Oncol, Anyang, Peoples R China
[2] Henan Univ Sci & Technol, Affiliated Hosp 1, Dept Med Oncol, Luoyang, Peoples R China
[3] Henan Canc Hosp, Dept Med Oncol, Zhengzhou, Peoples R China
[4] Shandong Univ, Qilu Hosp, Dept Radiat Oncol, Jinan, Peoples R China
[5] Shandong Canc Hosp, Dept Radiat Oncol, Jinan, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.1954
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1448P
引用
收藏
页码：S910 / S911
页数：2
相关论文
共 50 条
  • [31] A single-arm, open-label phase II clinical trial of SHR-1210 (camrelizumab) in combination with nimotuzumab in the second-line treatment of advanced esophageal squamous cell carcinoma.
    Wang, Feng
    Xia, Jin
    Meng, Xiangrui
    Ji, Yinghua
    Yang, Xiuli
    Hong, Yong-Gui
    Wang, Junsheng
    Cui, Donghai
    Luo, Zhiquan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [32] Recombinant human endostatin plus paclitaxel/nedaplatin for recurrent or metastatic advanced esophageal squamous cell carcinoma: a prospective, single-arm, open-label, phase II study
    Zhi-Qiang Wang
    De-Shen Wang
    Feng-Hua Wang
    Chao Ren
    Qiong Tan
    Yu-Hong Li
    Investigational New Drugs, 2021, 39 : 516 - 523
  • [33] Recombinant human endostatin plus paclitaxel/nedaplatin for recurrent or metastatic advanced esophageal squamous cell carcinoma: a prospective, single-arm, open-label, phase II study
    Wang, Zhi-Qiang
    Wang, De-Shen
    Wang, Feng-Hua
    Ren, Chao
    Tan, Qiong
    Li, Yu-Hong
    INVESTIGATIONAL NEW DRUGS, 2021, 39 (02) : 516 - 523
  • [34] Camrelizumab combined with albumin paclitaxel and platinum in perioperative treatment of resectable squamous cell lung cancer: A single-arm, open-label, phase II clinical trial
    Zhang, Y.
    Liu, S.
    Yang, L.
    Liu, Y.
    Wang, C.
    Han, Y.
    Xiao, B.
    Yan, D.
    Gong, C.
    Wang, F.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S978 - S978
  • [35] Anlotinib plus Epirubicin Followed by Anlotinib Maintenance as First-line Treatment for Advanced Soft-tissue Sarcoma: An Open-label, Single-arm, Phase II Trial
    Wang, Zhi-ming
    Zhuang, Rong-yuan
    Guo, Xi
    Zhang, Chen-lu
    You, Yang
    Chen, Li-sha
    Liu, Wen-shuai
    Zhang, Yong
    Luo, Rong-kui
    Hou, Ying-yong
    Lu, Wei-qi
    Zhou, Yu-hong
    CLINICAL CANCER RESEARCH, 2022, 28 (24) : 5290 - 5296
  • [36] Axitinib in first-line for patients with metastatic papillary renal cell carcinoma: Results of the multicentre, open-label, single-arm, phase II AXIPAP trial
    Negrier, Sylvie
    Rioux-Leclercq, Nathalie
    Ferlay, Celine
    Gross-Goupil, Marine
    Gravis, Gwenaelle
    Geoffrois, Lionel
    Chevreau, Christine
    Boyle, Helen
    Rolland, Frederic
    Blanc, Ellen
    Ravaud, Alain
    Dermeche, Slimane
    Flechon, Aude
    Albiges, Laurence
    Perol, David
    Escudier, Bernard
    EUROPEAN JOURNAL OF CANCER, 2020, 129 : 107 - 116
  • [37] A single-centre, prospective, open-label, single-arm trial of toripalimab with nab-paclitaxel and S-1 as a neoadjuvant therapy for esophageal squamous cell carcinoma (ESCC)
    Zhang, G.
    Hu, Y.
    Yang, B.
    Xu, Q.
    Li, J.
    Sun, S.
    Zhang, J.
    Jiao, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S722 - S722
  • [38] Anlotinib plus TQB2450 (PD-L1 blockade) combined with nab-paclitaxel and cisplatin as first-line treatment for advanced biliary tract cancer: A single-arm, open-label phase II clinical trial
    Jin, Shui-Ling
    Qiao, Shishi
    Li, Ren-Feng
    Zhang, Weijie
    He, Wei
    Su, Chang
    Li, Lu-Hao
    Pan, Jie
    Guo, Wen-Zhi
    Zong, Hong
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 498 - 498
  • [39] Camrelizumab in combination with preoperative chemotherapy for locally advanced esophageal squamous cell carcinoma: A single-arm, open-label, phase II study.
    Wang, Feng
    Qi, Yu
    Meng, Xiangrui
    Fan, Qingxia
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [40] Anlotinib plus sintilimab in patients with recurrent advanced endometrial cancer: A prospective open-label, single-arm, phase II clinical trial
    Wei, W.
    Ban, X.
    Yang, F.
    Huang, Y.
    Li, J.
    Cheng, X.
    Zheng, M.
    Li, J.
    ANNALS OF ONCOLOGY, 2021, 32 : S762 - S762
12345